Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose radiotherapy plus tislelizumab and platinum-etoposide for first-line extensive-stage small cell lung cancer
ChiCTR2500103289Phase 2Not yet recruiting
- Sponsor
- Renmin Hospital, Hubei University of Medicine
- Start
- Jun 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, etoposide, cisplatin and carboplatin in small cell lung cancer (SCLC), sponsored by Renmin Hospital, Hubei University of Medicine. Primary endpoints: Progression-free survival and Overall survival. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
tislelizumabetoposidecisplatincarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500103289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103289.